Huntington's disease (HD) is caused by CAG repeat expansion in the huntingtin gene, producing mutant huntingtin (mHTT) protein that undergoes pathological processing and aggregation. The heterogeneous nature of mHTT species—including full-length protein, N-terminal fragments of varying sizes, soluble oligomers, and insoluble aggregates—presents a complex therapeutic challenge. Current evidence suggests differential toxicity profiles among these species, with soluble oligomers potentially being more neurotoxic than large aggregates, while N-terminal fragments may have enhanced pathogenicity compared to full-length protein. This study aims to systematically validate mHTT clearance mechanisms as therapeutic targets by comprehensively characterizing the pathogenic potential of distinct mHTT species and evaluating targeted clearance strategies. Using human iPSC-derived neurons and organoids from HD patients with varying CAG repeat lengths, we will employ advanced biochemical fractionation, single-cell analysis, and longitudinal imaging to track mHTT species dynamics....
Huntington's disease (HD) is caused by CAG repeat expansion in the huntingtin gene, producing mutant huntingtin (mHTT) protein that undergoes pathological processing and aggregation. The heterogeneous nature of mHTT species—including full-length protein, N-terminal fragments of varying sizes, soluble oligomers, and insoluble aggregates—presents a complex therapeutic challenge. Current evidence suggests differential toxicity profiles among these species, with soluble oligomers potentially being more neurotoxic than large aggregates, while N-terminal fragments may have enhanced pathogenicity compared to full-length protein. This study aims to systematically validate mHTT clearance mechanisms as therapeutic targets by comprehensively characterizing the pathogenic potential of distinct mHTT species and evaluating targeted clearance strategies. Using human iPSC-derived neurons and organoids from HD patients with varying CAG repeat lengths, we will employ advanced biochemical fractionation, single-cell analysis, and longitudinal imaging to track mHTT species dynamics. Key innovations include development of species-specific detection methods using novel antibodies and mass spectrometry, implementation of optogenetic autophagy stimulation systems, and real-time monitoring of protein clearance kinetics. The study will test multiple therapeutic modalities including autophagy enhancers (rapamycin, trehalose), proteasome activators, and antisense oligonucleotides, measuring their differential effects on various mHTT species. Primary endpoints include quantitative assessment of neuronal viability, synaptic function, and transcriptional dysregulation in response to species-specific clearance. This work addresses critical gaps in understanding which mHTT species drive neurodegeneration and whether sustained protein lowering can be achieved without compensatory upregulation. Results will inform rational therapeutic design by identifying optimal targets within the mHTT clearance pathway and establishing biomarkers for monitoring therapeutic efficacy in clinical applications.
This experiment directly tests predictions arising from the following hypotheses:
Transcriptional Autophagy-Lysosome Coupling
Autophagosome Maturation Checkpoint Control
Stress Granule Phase Separation Modulators
Heat Shock Protein 70 Disaggregase Amplification
VCP-Mediated Autophagy Enhancement
Experimental Protocol
Phase 1 (Weeks 1-4): Generate human iPSC-derived striatal and cortical neurons from HD patients (n=6 lines, 18-72 CAG repeats) and controls (n=3 lines). Culture neurons for 8-12 weeks to achieve mature mHTT expression patterns. Phase 2 (Weeks 5-8): Perform comprehensive mHTT species characterization using sequential biochemical fractionation (RIPA, urea, formic acid extraction), followed by Western blotting with species-specific antibodies (anti-HTT N-terminus, polyQ-specific, aggregate-preferring) and quantitative mass spectrometry. Phase 3 (Weeks 9-16): Implement therapeutic interventions in 96-well format with n=8 replicates per condition: autophagy enhancers (rapamycin 100nM, trehalose 100mM), proteasome activators (PA28γ overexpression), and huntingtin-lowering ASOs (10μM). Monitor mHTT species levels at 24h, 72h, 1 week, and 2 weeks post-treatment using automated high-content imaging and biochemical analysis. Phase 4 (Weeks 17-20): Assess functional outcomes including neuronal viability (calcein-AM/propidium iodide), synaptic function (calcium imaging, electrophysiology), and transcriptional profiling (RNA-seq, n=4 biological replicates). Phase 5 (Weeks 21-24): Validate findings in 3D organoid models (n=5 organoids per condition) and perform compensatory upregulation analysis using qPCR and Western blotting for huntingtin, autophagy markers (LC3, p62), and stress response genes.
Expected Outcomes
Soluble mHTT oligomers will demonstrate 2-3 fold higher neurotoxicity compared to aggregated species, with IC50 values differing by >50% in viability assays (p<0.01)
N-terminal mHTT fragments (<500 amino acids) will show 40-60% greater pathogenic potential than full-length protein based on transcriptional dysregulation signatures
Autophagy enhancement will preferentially clear soluble mHTT species (60-80% reduction) while having minimal effect on large aggregates (<20% reduction)
Huntingtin-lowering ASOs will achieve 70-90% reduction in total mHTT but trigger 2-4 fold compensatory upregulation of autophagy genes within 48-72 hours
Combined autophagy enhancement and moderate huntingtin lowering (40-60%) will provide optimal neuroprotection with 80-90% preservation of synaptic function
CAG repeat length will correlate positively with oligomer formation rate (R²>0.7) and negatively with aggregate clearance efficiency (R²>0.6)
Success Criteria
Establish quantitative hierarchy of mHTT species toxicity with statistically significant differences (p<0.05) between at least 3 distinct species
Achieve >50% selective clearance of target mHTT species using at least 2 different therapeutic approaches without affecting normal huntingtin function
Demonstrate sustained mHTT lowering (>60% reduction maintained for 2 weeks) with minimal compensatory upregulation (<2-fold increase in clearance pathway genes)
Identify biomarker signatures that predict therapeutic response with >80% accuracy across different CAG repeat lengths
Validate lead therapeutic combinations showing >70% neuroprotection in both 2D neuronal cultures and 3D organoid models
Establish dose-response relationships for therapeutic interventions with clear therapeutic windows (>3-fold difference between effective and toxic doses)
Phase 1 (Weeks 1-4): Generate human iPSC-derived striatal and cortical neurons from HD patients (n=6 lines, 18-72 CAG repeats) and controls (n=3 lines). Culture neurons for 8-12 weeks to achieve mature mHTT expression patterns. Phase 2 (Weeks 5-8): Perform comprehensive mHTT species characterization using sequential biochemical fractionation (RIPA, urea, formic acid extraction), followed by Western blotting with species-specific antibodies (anti-HTT N-terminus, polyQ-specific, aggregate-preferring) and quantitative mass spectrometry. Phase 3 (Weeks 9-16): Implement therapeutic interventions in 96-well format with n=8 replicates per condition: autophagy enhancers (rapamycin 100nM, trehalose 100mM), proteasome activators (PA28γ overexpression), and huntingtin-lowering ASOs (10μM).
...
Phase 1 (Weeks 1-4): Generate human iPSC-derived striatal and cortical neurons from HD patients (n=6 lines, 18-72 CAG repeats) and controls (n=3 lines). Culture neurons for 8-12 weeks to achieve mature mHTT expression patterns. Phase 2 (Weeks 5-8): Perform comprehensive mHTT species characterization using sequential biochemical fractionation (RIPA, urea, formic acid extraction), followed by Western blotting with species-specific antibodies (anti-HTT N-terminus, polyQ-specific, aggregate-preferring) and quantitative mass spectrometry. Phase 3 (Weeks 9-16): Implement therapeutic interventions in 96-well format with n=8 replicates per condition: autophagy enhancers (rapamycin 100nM, trehalose 100mM), proteasome activators (PA28γ overexpression), and huntingtin-lowering ASOs (10μM). Monitor mHTT species levels at 24h, 72h, 1 week, and 2 weeks post-treatment using automated high-content imaging and biochemical analysis. Phase 4 (Weeks 17-20): Assess functional outcomes including neuronal viability (calcein-AM/propidium iodide), synaptic function (calcium imaging, electrophysiology), and transcriptional profiling (RNA-seq, n=4 biological replicates). Phase 5 (Weeks 21-24): Validate findings in 3D organoid models (n=5 organoids per condition) and perform compensatory upregulation analysis using qPCR and Western blotting for huntingtin, autophagy markers (LC3, p62), and stress response genes.
Expected Outcomes
Soluble mHTT oligomers will demonstrate 2-3 fold higher neurotoxicity compared to aggregated species, with IC50 values differing by >50% in viability assays (p<0.01)
N-terminal mHTT fragments (<500 amino acids) will show 40-60% greater pathogenic potential than full-length protein based on transcriptional dysregulation signatures
Autophagy enhancement will preferentially clear soluble mHTT species (60-80% reduction) while having minimal effect on large aggregates (<20% reduction)
Huntingtin-lowering ASOs will achieve 70-90% reduction in total mHTT but trigger 2-4 fold compensatory upreg
...
Soluble mHTT oligomers will demonstrate 2-3 fold higher neurotoxicity compared to aggregated species, with IC50 values differing by >50% in viability assays (p<0.01)
N-terminal mHTT fragments (<500 amino acids) will show 40-60% greater pathogenic potential than full-length protein based on transcriptional dysregulation signatures
Autophagy enhancement will preferentially clear soluble mHTT species (60-80% reduction) while having minimal effect on large aggregates (<20% reduction)
Huntingtin-lowering ASOs will achieve 70-90% reduction in total mHTT but trigger 2-4 fold compensatory upregulation of autophagy genes within 48-72 hours
Combined autophagy enhancement and moderate huntingtin lowering (40-60%) will provide optimal neuroprotection with 80-90% preservation of synaptic function
CAG repeat length will correlate positively with oligomer formation rate (R²>0.7) and negatively with aggregate clearance efficiency (R²>0.6)
Success Criteria
Establish quantitative hierarchy of mHTT species toxicity with statistically significant differences (p<0.05) between at least 3 distinct species
Achieve >50% selective clearance of target mHTT species using at least 2 different therapeutic approaches without affecting normal huntingtin function
Demonstrate sustained mHTT lowering (>60% reduction maintained for 2 weeks) with minimal compensatory upregulation (<2-fold increase in clearance pathway genes)
Identify biomarker signatures that predict therapeutic response with >80% accuracy across different CAG repeat lengths
Validate lead
...
Establish quantitative hierarchy of mHTT species toxicity with statistically significant differences (p<0.05) between at least 3 distinct species
Achieve >50% selective clearance of target mHTT species using at least 2 different therapeutic approaches without affecting normal huntingtin function
Demonstrate sustained mHTT lowering (>60% reduction maintained for 2 weeks) with minimal compensatory upregulation (<2-fold increase in clearance pathway genes)
Identify biomarker signatures that predict therapeutic response with >80% accuracy across different CAG repeat lengths
Validate lead therapeutic combinations showing >70% neuroprotection in both 2D neuronal cultures and 3D organoid models
Establish dose-response relationships for therapeutic interventions with clear therapeutic windows (>3-fold difference between effective and toxic doses)